EU competition officials are scrutinising deals in which Big Pharma companies are "paying off" generic rivals in return for a delay in the launch of cheaper copies.
They estimate delayed introduction of generic medicines added €3bn to healthcare costs for patients and taxpayers from 2000 to 2007.
More at the FT
No comments:
Post a Comment